ASCO-SITC Clinical Immuno-Oncology Symposium

01/25/18

From January 25-27, the American Society of Clinical Oncology hosted its Clinical Immuno-Oncology Symposium in San Francisco, California. The meeting will highlight some of the largest updates in clinical and translational research in immuno-oncology and the implications for clinical care. Journal of Clinical Pathways will be covering the most relevant abstracts of the meeting.


side
 
A recent survey highlighted the need for educational resources to go further in-depth into immunotherapy science and management strategies for treatment-related adverse events.
 
 
 
PD1
 
Immunotherapy treatment past progression for patients with advanced lung cancer may account for 29% of total treatment costs, without clear value for most patients.
 
 
 
 
 

In recent years, there has been a significant increase in hospitalizations, readmissions, and deaths due to immune-related adverse events from immune checkpoint inhibitors.

Read More